Research programme: AAV gene therapies - Dyno Therapeutics
Latest Information Update: 28 Jun 2024
At a glance
- Originator Dynogen Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Liver disorders
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in CNS-disorders in USA (Parenteral)
- 28 Jun 2024 No recent reports of development identified for research development in Liver-disorders in USA (Parenteral)
- 12 May 2020 Dyno Therapeutics has an option to in-license CapsidMap platform technology from Harvard University